About Us
Medisafe is the leading medication engagement platform that empowers patients to seamlessly manage their treatment
Our Values
We Care
Our motivation is driving positive outcomes for our users, partners and team members.
We Dare
We seize opportunities, take risks, and relish learning from failure.
We Assume Ownership
We expect accountability and seek like-minded A-players who bring passion to our mission.
We Deliver
We embrace creative ideas and focus on execution that excels.
We Are Open
We love feedback and are honest and direct in our communication.
Board of Directors
Board Chairwoman
Lynn O’Connor Vos
CEO, Co-founder
Omri Shor
Managing Partner
7wire Ventures
Lee Shapiro
Co-Founder, Managing Partner
ALIVE Israel HealthTech Fund
Dudi Klein
Global Head, Digital Investments
Sanofi Ventures
Cris De Luca
Managing General Partner
Pitango Venture Capital
Ittai Harel
General Partner
Lool Ventures
Avichay Nissenbaum
Executives
CTO, Co-founder
Rotem Shor
Chief Business Officer
Stacey Wasserman
Chief Financial Officer
Erez Kahani
Our Investors
It Begins with Our Digital Companion
Personalized support for everyone. The integrated medication engagement platform incorporates interventions from across the ecosystem.
Just-In-Time-Interventions (JITI)
JITI powers Medisafe’s patient engagement platform as the predictive machine-learning engine driving personalized patient support. Learn More
Medisafe Maestro
Advanced technology that seamlessly orchestrates treatment journeys with precision and speed, digitizing support through personalized delivery. Learn More
Care Integration Engine
Design optimal patient journeys with technology that meets patients’ evolving needs through integrations that connect support throughout the ecosystem. Learn More
The Latest From Medisafe
Transforming Breast Cancer Care: Proven Adherence Gains for Pharma Execs
Summary Breast cancer remains one of the most prevalent malignancies worldwide, with an estimated 287,850 new invasive cases and 43,250 breast cancer–related deaths projected in the United States in 2025 (American Cancer Society, 2025). Despite advances in targeted oral therapies for extended adjuvant treatment, real‐world studies find that up to 50% of patients discontinue or skip doses, undermining efficacy (Mayo Clinic, 2024). Pharmaceutical stakeholders…